Tag: HER2-positive
Peptide–drug Conjugate Sudocetaxel Zendusortide Shows Potential as a Single Agent and...
Sudocetaxel zendusortide, also known as TH1902, is as novel, investigational peptide-drug conjugate (PDC) candidate being developed by Canadian biotech Theratechnologies as single agent and in combination with other anticancer therapies. The drug targets tumors that express the sortilin (SORT1) receptor.
European Medicines Agency Validates Marketing Authorization Application for Trastuzumab Duocarmazine
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Byondis’ investigational next generation anti-HER2 antibody-drug conjugate (ADC) trastuzumab duocarmazine* in patients...
First ‘Intelligent Ligase-dependent Conjugation’ Enabling ADC Receives FDA IND Clearance
This week, GeneQuantum Healthcare, a Suzhou, China-based developer of bioconjugate drugs, confirmed that the company has received an Investigational New Drug (IND) approval for...
IND for RemeGen’s Disitamab Vedotin Marks Important Milestone for the Company’s...
The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application allowing Yantai (Shandong Province; China) -based biopharmaceutical company RemeGen...
Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced...
Following initiation of pivotal phase II studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase II study in colorectal...
Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...
Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...
About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...
Mersana and Takeda Expand Partnership to Advance Development of Fleximer® based...
Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new, expanded, strategic partnership. Under the terms of the agreement, Takeda...
Preclinical Data Confirms Therapeutic Potential of SYD985 in Patients with Low...
Preclinical data of SYD985, presented by Synthon Biopharmaceutical's Gijs Verheijden during the 37th Annual San Antonio Breast Cancer Symposium (SABCS), being held at The...
Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...
Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.
